🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the battle against drug-resistant strains of the bacteria, according to health experts.

A Global Public Health Issue

The sexually transmitted infection are increasing around the world, with data suggesting over 82 million infections annually. Especially elevated rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary step in the face of growing infection rates, the spread of superbugs and the very limited therapeutic options at this time.”

Medical experts are increasingly worried about the rise in treatment-resistant strains. The World Health Organization has designated it as a "critical concern". Ongoing monitoring revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Secure Authorization

Zoliflodacin, marketed under the name a brand name, was approved by the US FDA in December for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts hope that specific application of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This medication, which is also used to treat urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization marks a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been outpacing medical innovation.”

Research Study Data and Global Access

As per findings published in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the existing first-line therapy, which combines an injection and a pill. The trial enrolled nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the authority to register and commercialise the drug in numerous regions with limited resources.

Clinicians on the front lines have shared positive views. Having a one-pill regimen of this kind is described as a "revolutionary step" for public health efforts. This is considered essential to lessen the impact of the disease for people and to halt the transmission of highly drug-resistant gonorrhoea around the world.